13 янв. 2020 г. · In adult outpatients with moderate to severe UC, the AGA recommends using infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, or ...

In adult outpatients with moderate-to-severe ulcerative colitis (UC), AGA recommends using infliximab, adalimumab, golimumab, vedolizumab, tofacitinib or ...

18 дек. 2018 г. · In patients with extensive or left-sided mild–moderate ulcerative colitis, the AGA suggests adding rectal mesalamine to oral 5-ASA. Conditional ...

8 июл. 2024 г. · The AGA Living Guideline: Pharmacological Management of Moderate-To-Severe Ulcerative Colitis will be published in December 2024.

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 Apr;158(5):1450-1461.

This document presents the official recommendations of the American Gastroenterological Association (AGA) on the management of mild-moderate ulcerative colitis.

3 окт. 2024 г. · The American Gastroenterological Association (AGA) released new guidelines on the management of mild-to-moderate ulcerative colitis (UC) in ...

In adult outpatients with moderate-to-severe UC, the AGA recommends the use of infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ...

These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American ...

Running title: Living guidelines for moderate-to-severe ulcerative colitis ... since the publication of the most recent AGA guideline for treatment of moderate-to ...